TickerLeague

Buyback Spend for Viatris (VTRS)

Buyback Spend for Viatris (VTRS): headline value $500.50M · YoY +100.2%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Latest period

$500.50M

YoY change

+100.2%

5Y CAGR

N/A

Peak year (2005)

$1.26B

Latest annual

$500.50M

Buyback Spend history chart for Viatris (VTRS) from 2003 to 2025

Buyback Spend history table for Viatris (VTRS) from 2003 to 2025

Fiscal yearPeriod endedReportedBuyback SpendYoY
2025$500.50M+100.2%
2024$250.00M0.0%
2023$250.00M
2022$0-100.0%
2021$17.40M
2020$0
2019$0-100.0%
2018$432.00M-13.6%
2017$500.20M+2758.3%
2016$17.50M-74.1%
2015$67.50M+143.7%
2014$27.70M-97.2%
2013$1.00B+0.0%
2012$999.90M+185.7%
2011$350.00M
2010$0
2009$0
2008$0
2007$0
2005$1.26B
2004$0-100.0%
2003$133.09M

Buyback Spend values are taken from Viatris's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

Analysis

As of the 2025 fiscal year, Viatris (VTRS) reported buyback spend of $500.50M – surged 100.2% year-over-year.

Viatris buyback spend compound annual growth for the 2015–2025 (10 years) window is +22.2%, with the latest reading among the more recent periods of the dataset.

Viatris buyback spend plunged from $1.26B in 2005 to $500.50M in 2025, a 60.2% drawdown.

$1.26B stands as the all-time-high annual buyback spend, posted in 2005, against a low of $0 during 2004.

Viatris (VTRS) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.

Viatris Buyback Spend by Year

Viatris Buyback Spend 2025: $500.50M

Viatris buyback spend in 2025 was $500.50M, surged 100.2% from 2024.

Viatris Buyback Spend 2024: $250.00M

Viatris buyback spend in 2024 was $250.00M, edged up 0.0% from 2023.

Viatris Buyback Spend 2023: $250.00M

Viatris buyback spend in 2023 was $250.00M.

Viatris Buyback Spend 2022: $0

Viatris buyback spend in 2022 was $0, plunged 100.0% below 2021.

Viatris Buyback Spend 2021: $17.40M

Viatris buyback spend in 2021 was $17.40M.

See more financial history for Viatris (VTRS).

Sector peers — Buyback Spend

Companies in the same sector as Viatris, ranked by their latest buyback spend.

CompanyBuyback SpendSector
Johnson & Johnson (JNJ)$5.95BHealthcare
UnitedHealth Group Incorporated (UNH)$5.54BHealthcare
Merck & Co., Inc. (MRK)$5.08BHealthcare
Eli Lilly and Company (LLY)$4.11BHealthcare
Novo Nordisk A/S (NVO)$1.39BHealthcare
AbbVie Inc. (ABBV)$980.00MHealthcare
AstraZeneca PLC (AZN)$719.66MHealthcare
Amgen Inc. (AMGN)$0Healthcare

Frequently asked questions

What is Viatris's buyback spend?

Latest reported buyback spend for Viatris (VTRS) is $500.50M (period ending December 31, 2025).

How has Viatris buyback spend changed year-over-year?

Viatris (VTRS) buyback spend changed +100.2% year-over-year on the latest annual filing.

What is the long-term growth rate of Viatris buyback spend?

Viatris (VTRS) buyback spend compound annual growth rate is +22.2% over the most recent 10 years available.

When did Viatris buyback spend hit its highest annual value?

Viatris buyback spend reached its highest annual value of $1.26B in 2005.

What was Viatris buyback spend in 2024?

Viatris (VTRS) buyback spend in 2024 was $250.00M.

What was Viatris buyback spend in 2025?

Viatris (VTRS) buyback spend in 2025 was $500.50M.

Metrics overview

Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.